← back to search

Alberto Órfão

Centre for Biomedical Network Research on Rare Diseases · ES
Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, and Acute Lymphoblastic Leukemia research.
h-index
93
citations
59,332
works
935
NIH funding
primary concept
Medicine
email

Recent publications

Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
The Journal of Allergy and Clinical Immunology In Practice 2024cited by 28position: middledoi
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
The Lancet Haematology 2024cited by 27position: middledoi
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
The Journal of Allergy and Clinical Immunology In Practice 2023cited by 45position: middledoi
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
The Journal of Allergy and Clinical Immunology In Practice 2023cited by 10position: middledoi
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood 2022cited by 2,593position: middledoi
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 86position: middledoi
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 69position: middledoi
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 51position: middledoi
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues
Cytometry Part B Clinical Cytometry 2022cited by 47position: middledoi
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 26position: middledoi
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 26position: middledoi
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
Blood 2022cited by 23position: middledoi
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 20position: middledoi
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 11position: middledoi
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
HemaSphere 2021cited by 288position: middledoi
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
The Journal of Allergy and Clinical Immunology In Practice 2021cited by 74position: middledoi
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
Blood Cancer Journal 2021cited by 71position: middledoi
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
The Lancet Haematology 2021cited by 65position: lastdoi
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Clinical Cancer Research 2021cited by 64position: middledoi
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp>
Cytometry Part B Clinical Cytometry 2021cited by 44position: middledoi
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
The Journal of Allergy and Clinical Immunology In Practice 2021cited by 41position: middledoi
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group
Cytometry Part B Clinical Cytometry 2021cited by 38position: middledoi
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis
The American Journal of Human Genetics 2021cited by 19position: middledoi
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Theranostics 2020cited by 182position: middledoi
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
Journal of Allergy and Clinical Immunology 2020cited by 32position: middledoi
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
The Lancet Haematology 2019cited by 137position: middledoi
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Haematologica 2019cited by 136position: middledoi
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia 2019cited by 65position: middledoi
Lmo2 expression defines tumor cell identity during T‐cell leukemogenesis
The EMBO Journal 2018cited by 38position: middledoi
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
Cancer Research 2017cited by 246position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Stephen J. Galli · Stanford University2 papers (2017–2020)Peter Valent · Ec3 NetWorks (Austria)2 papers (2017–2020)Dean D. Metcalfe · Charité - Universitätsmedizin Berlin2 papers (2017–2020)Tracy I. George · University of Utah2 papers (2017–2020) · 2 papers (2017–2020)Karl Sotlar · Paracelsus Medical University2 papers (2017–2020)Olivier Hermine · Institut de Biologie Moléculaire et Cellulaire2 papers (2017–2020)Jason Gotlib · University of California, San Francisco2 papers (2017–2020)Wolfgang R. Sperr · Medical University of Vienna2 papers (2017–2020)Cem Akin · University of Michigan2 papers (2017–2020)Vanessa Rebecca Gasparini · University of Padua1 papers (2022–2022)Javier De Las Rivas · Universidad de Salamanca1 papers (2012–2012) · 1 papers (2021–2021)Xiaoyu Jiang · Dhurakij Pundit University1 papers (2012–2012) · 1 papers (2014–2014)Andreas Reiter · University of Augsburg1 papers (2020–2020) · 1 papers (2020–2020) · 1 papers (2012–2012)Hans‐Peter Horny · Technical University of Munich1 papers (2020–2020) · 1 papers (2014–2014)